I3X-MC-JHTB: A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514254-69-00

Acronym

I3X-MC-JHTB

Enrollment

Registered

2024-12-09

Start date

2012-10-22

Completion date

Unknown

Last updated

2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

and polycythemia vera, essential thrombocythemia, myelofibrosis, Myeloproliferative neoplasms (MPNs)

Brief summary

The primary objective of this study is to assess the activity of LY2784544 therapy administered once daily, as measured by objective response rate, in patients with the myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocytopenia (ET) or myelofibrosos (MF) including those who have demonstrated an intolerance to, failure of primary response to, or have demonstarted disease progression while on ruxolitinib.

Detailed description

To characterise the toxicity profile To assess response criteria To assess efficacy To characterise PD-PHK

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary objective of this study is to assess the activity of LY2784544 therapy administered once daily, as measured by objective response rate, in patients with the myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocytopenia (ET) or myelofibrosos (MF) including those who have demonstrated an intolerance to, failure of primary response to, or have demonstarted disease progression while on ruxolitinib.	—

Measure

Time frame

—

Secondary

Measure	Time frame
To characterise the toxicity profile To assess response criteria To assess efficacy To characterise PD-PHK	—

Countries

Austria, Germany, Spain

Outcome results